• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Empaglifozin reduces death in heart failure patients with preserved ejection fraction

byBoaz WongandHarsh Shah
November 2, 2021
in Cardiology, Chronic Disease, Endocrinology, Nephrology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Empaglifozin treatment was shown to have reduced rates of cardiovascular death or hospitalization in patients with heart failure and preserved ejection fraction.

2. Both treatment groups had a similar percentage of patients discontinuing the therapy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs shown to reduce the progression of heart failure in patients with reduced ejection fraction; however, this effect is unknown in heart failure patients with preserved ejection fraction. In this randomized control trial, patients with chronic heart failure and left ventricular ejection fraction of more than 40% were randomized to either receive 10mg of empagliflozin once daily or placebo treatment. The primary outcome was the incidence of cardiovascular death or hospitalization solely due to heart failure events. The study found that empagliflozin treatment was able to lower the risk of hospitalization compared to the placebo group, but the effect was not observed for cardiovascular deaths. This effect was found irrespective of patient diabetes status. Rates of serious adverse events were similar between the two groups. The study was limited by a high rate of discontinuation amongst both groups for reasons other than death. Together, this study establishes the basis of empagliflozin use in patients with heart failure and preserved ejection fraction to prevent adverse cardiovascular outcomes.

Click to read the study in NEJM

Relevant Reading: SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

In-Depth [randomized controlled trial]: In this randomized controlled trial, 5988 patients were enrolled from 622 centers in 23 countries. Patients with a New York Heart Association functional class II-IV chronic heart failure and a left ventricular ejection fraction greater than 40% were included in the study. Patients were excluded if they had a disorder that would change their clinical course. The patients were randomized in a 1:1 ratio to either receive empagliflozin (10mg) or placebo treatment, respectively. Groups were also stratified by geographic region, diabetes status, estimated glomerular filtration rate (eGFR), and left ventricular ejection fraction greater than 50%. The primary outcome was the time between first treatment and incidence of cardiovascular-related hospitalization or death due to heart failure. In a median of 26.2 months to first event, 415 (13.8%) patients receiving empagliflozin experience the primary outcome compared to 511 (17.1%) patients in the placebo group 9hazard ratio [HR], 0.79; 95%confidence interval [CI], 0.69 to 0.90; P<0.001). When the primary outcomes were separated, patients receiving empagliflozin continued to demonstrate a lower rate of hospitalizations than the placebo group (HR, 0.71; 95%CI, 0.60 to 0.83). Conversely, the effect was not significant for the incidence of heart failure-related deaths (HR, 0.91; 95%CI, 0.76 to 1.09). These effects were also observed when patients were stratified for diabetes status. Altogether, the study supports the use of empagliflozin in heart failure patients with a preserved ejection fraction.

RELATED REPORTS

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease

Empagliflozin use is associated with slower progression of chronic kidney disease

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular eventscardiovascular mortalitydiabeteseGFRempaglifozinheart failureHFpEF (heart failure with preserved ejection fractionSGLT-2 inhibitors
Previous Post

Multimodal physical interventions may lower concussion symptom scores

Next Post

COVID-19-related hospital policies not associated with delays in urgent open and closed fracture surgeries compared to pre-pandemic

RelatedReports

Intravenous contrast may not increase risk of acute kidney injury
Chronic Disease

Cystatin C-based equation without race or sex improves accuracy of GFR estimation

February 3, 2023
CPAP may not decrease cardiovascular events in sleep apnea
Endocrinology

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease

February 2, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Torsemide not associated with significant difference in all-cause mortality over 12 months compared to furosemide – The TRANSFORM-HF randomized clinical trial

January 24, 2023
Next Post
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery

COVID-19-related hospital policies not associated with delays in urgent open and closed fracture surgeries compared to pre-pandemic

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Systematic screening for atrial fibrillation may reduce morbidity and mortality in older patients

Poverty, preterm birth demonstrate additive effect on cognition

Phototherapy not associated with increased risk of childhood cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options